109 results about "Serology" patented technology

The invention relates to the technical field of biology, and aims to provide a monoclonal antibody 7A12 for identifying gene type 2 swine fever as well as a preparation method and an application method of the monoclonal antibody 7A12. The monoclonal antibody comprises Ig structural domains VH CDR1, VH CDR2 and VH CDR3 of a heavy chain of the antibody, and Ig structural domains VL CDR1, VL CDR2 and VL CDR3 of a light chain of the antibody, wherein the amino acid sequences of the VH CDR1, the VH CDR2 and the VH CDR3 are respectively as shown in SEQ ID NO: 1 to SEQ ID NO: 3; the amino acid sequences of the VL CDR1, the VL CDR2 and the VL CDR3 are respectively as shown in SEQ ID NO: 4 to SEQ ID NO: 6. The antibody provided by the invention has the advantages of high titer, strong specificity, high affinity and the like; the kit has the advantages of high sensitivity and strong specificity, has no cross reaction with the type 1 swine fever vaccine strain, and can identify and diagnose swine fever gene type 2 wild strain infection and vaccine immunity in serology; the method can be further used for establishing a blocking ELISA kit for identifying the gene type 2 hog cholera, and can effectively diagnose and purify the gene type 2 hog cholera virus.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

The present invention discloses an application of a nano-luciferase fusion antigen in the detection of African swine fever virus antibodies. The fusion antigen is composed of LgBiT-p30 and SmBiT-p30 proteins, which are fused and expressed by two subunits of nano-luciferase, LgBiT and SmBiT, respectively, with the African swine fever virus p30 protein. The fusion antigen can bind to a specific antibody against the African swine fever virus p30 protein to form a functional luciferase, which reacts with a substrate to produce a bright luminescent signal. The fusion antigen has high specificity and sensitivity in the detection of African swine fever virus antibodies, making the antibody detection process more efficient and rapid. The present invention realizes simple, rapid, sensitive and specific detection of African swine fever virus antibodies, and provides an innovative and reliable solution for the serological diagnosis of African swine fever.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention discloses miRNAs (micro Ribonucleic Acid) of small extracellular vesicles of blood, wherein the miRNAs comprise hsa-let-7d-3p, hsa-let-7f-5p, hsa-let-7i-5p, hsa-miR-140-5p, hsa-miR-142-3p, hsa-miR-21-5p, hsa-miR-26a-5p and hsa-miR-99a-5p. The miRNAs can be used as biomarkers for early diagnosis of lung cancer, especially for distinguishing patients with early lung cancer and people with high risk of lung cancer. The specificity of the blood extracellular vesicle miRNA biomarker for distinguishing early-stage lung cancer patients and high-risk people is higher than that of existing clinical imaging and serology methods, excessive diagnosis and treatment can be effectively reduced, and therefore the blood extracellular vesicle miRNA biomarker has good clinical application value.

The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with α-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of α-synuclein-based biomarkers from low volumes of biological samples.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

The application belongs to the field of biotechnology detection, and particularly relates to a multiplex PCR detection kit for identifying and distinguishing chicken pullorum salmonella and chicken typhoid salmonella. The kit comprises stn gene detection primers, I137_14445 gene detection primers and ybgL gene detection primers. The kit can quickly, high-throughput and accurately identify and distinguish chicken pullorum salmonella and chicken typhoid salmonella, can replace traditional salmonella serological typing and biochemical identification and other complex procedures, and provides a simple, rapid, reproducible new method for monitoring and laboratory diagnosis of chicken pullorum salmonella and chicken typhoid salmonella.

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

This invention relates to the field of biotechnology, and aims to provide a monoclonal antibody 7A12 for identifying genotype 2 classical swine fever, along with its preparation and application methods. This monoclonal antibody contains an Ig domain V of the antibody heavy chain. H CDR1, V H CDR2 and V H CDR3, and the Ig domain V of the antibody light chain L CDR1, V L CDR2 and V L CDR3; wherein, the V H CDR1, V H CDR2 and V H The amino acid sequences of CDR3 are shown in SEQ ID NO:1-3, respectively; the V L CDR1, V L CDR2 and V L The amino acid sequences of CDR3 are shown in SEQ ID NO:4-6. The antibody provided by this invention has advantages such as high titer, strong specificity, and high affinity; it also has high sensitivity and specificity, and shows no cross-reactivity with type 1 classical swine fever vaccine strains. Serologically, it can differentiate and diagnose infection and vaccine immunization with genotype 2 classical swine fever wild-type strains. Furthermore, it can be used to develop a blocking ELISA kit for identifying genotype 2 classical swine fever, effectively diagnosing and purifying genotype 2 classical swine fever virus.

The invention belongs to the technical field of biology, and particularly relates to a detection method of a tumor serological marker. The application of the reagent for detecting the concentration of the sGRP78 protein in the serum of the breast cancer patient in preparation of a product for evaluating the curative effect of the breast cancer patient after neoadjuvant therapy is characterized in that the number of neoadjuvant therapy is four. In order to overcome the defects of dynamic monitoring deficiency, invasiveness, high cost and insufficient serum marker sensitivity in the existing neoadjuvant therapy metaphase evaluation of the breast cancer, the invention provides a detection kit, namely, the serum marker sGRP78 is monitored in the neoadjuvant therapy metaphase evaluation of the breast cancer, and the sensitivity of the serum marker sGRP78 in the neoadjuvant therapy metaphase evaluation of the breast cancer is improved. Therefore, a noninvasive, low-cost, high-sensitivity and high-specificity neoadjuvant therapy metaphase evaluation index is achieved.

The invention relates to an indirect ELISA (enzyme-linked immuno sorbent assay) detection kit for a sheep bacteroides nodules antibody and application thereof, belonging to the technical field of biological detection. In order to solve the technical problems that a bacterium separation identification and PCR (Polymerase Chain Reaction) detection method of bacteroides nodulosus has defects and a serological identification method for bacteroides nodulosus does not exist in the prior art, the invention adopts a sheep bacteroides nodulosus outer membrane protein Omp1D as a coating antigen in an indirect ELISA (Enzyme-Linked Immuno Sorbent Assay) detection kit; rapid detection and screening of bovine and sheep bacteroides nodules infection can be realized, and the kit has the characteristics of simple operation, rapidness and sensitivity, accurate result, good specificity and repeatability and the like; meanwhile, the indirect ELISA detection kit for the sheep bacteroides nodules antibody has the characteristics of being simple in preparation method, low in cost, suitable for large-scale production and the like, a rapid, simple and sensitive diagnostic kit for detecting bacteroides nodules infection is provided for large-scale breeding of animal husbandry, and a technical support is provided for preventing and controlling bacteroides nodules infection.

The present disclosure relates to single-chain antibodies that specifically bind to the cotton leafroll dwarf virus (CLRDV), and methods for using such antibodies in the serological or molecular detection of CLRDV in plant or aphid samples. In particular, the disclosure relates to single-chain antibodies that recognize the CLRDV coat protein (CP) or the CLRDV n-terminal read-through domain (NRTD).

The invention provides a polysaccharide antigen derived from salmonella pullorum and marked by fluorescent molecules as well as a preparation method and application of the polysaccharide antigen. The invention provides a simple, convenient and rapid extraction method of the salmonella pullorum polysaccharide antigen, and the polysaccharide antigen for bacterial serological detection is prepared by combining fluorescence labeling on the basis of the experimental principle of fluorescence polarization. The polysaccharide antigen prepared according to the method provided by the invention can be used for serological detection of salmonella pullorum and has good sensitivity, and a new method is provided for detection of salmonella pullorum infection.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

The invention discloses a diagnostic method based on mouse lyme disease serology indirect ELISA laboratory, and relates to the technical field of immunoserology detection.The diagnostic method comprises the steps that experimental conditions are optimized through a system, and the optimal reaction system is determined as follows: the antigen coating concentration is 0.2 microgram / microliter, the serum dilution ratio is 1: 200, and the enzyme-labeled secondary antibody concentration is 1: 2000. 0.8), and meanwhile, the antigen dosage is obviously reduced. Dynamic analysis of the antibody shows that the level of the antibody infecting mouse serum reaches a peak 12-25 days after inoculation, and the threshold value of the specific antibody ratio (ArB%) is 71.43%. Researches prove that the method has the characteristics of simplicity and convenience in operation, economy and high efficiency, and is suitable for primary laboratories and large-scale screening. The method provides reliable standardized technical support for lyme disease laboratory diagnosis and epidemiological monitoring.

The present invention discloses a broad-spectrum neutralizing monoclonal antibody against classical swine fever virus and its application, belonging to the field of immunoglobulins. Specifically, an antibody or its antigen-binding fragment is disclosed, which comprises a heavy-chain variable region and a light-chain variable region; the amino acid sequences of CDR1, CDR2, and CDR3 in the heavy-chain variable region sequentially comprise positions 9-15, 33-40, and 79-90 of SEQ ID No.1; the amino acid sequences of CDR1, CDR2, and CDR3 in the light-chain variable region sequentially comprise positions 21-31, 49-51, and 88-97 of SEQ ID No.3. The monoclonal antibody of the present invention can specifically react with all genotype strains of classical swine fever virus, and the established blocking ELISA method using it can detect classical swine fever virus E2 antibody. The monoclonal antibody of the present invention can be used for the identification of CSFV antigen and the development of serological antibody detection kits, providing antibody resources for the accurate diagnosis, prevention, control, and purification of CSFV.

The present application relates to the technical field of medical data mining, in particular to a whole-course management system based on fusion analysis of hepatitis B serological and virological indexes, which comprises a serum index collection module, an evolution path construction module, a characteristic section extraction module, an intervention response classification module and a fusion structure induction module.In the present application, based on the index sequence matrix formed by continuous sampling, the trend trajectory is generated by tracking the change direction of the index concentration at each time node, the change fragments with structural differences are extracted in combination with the biochemical response markers, the index combination relationship under different interventions is classified and arranged, the matching mapping between the intervention behavior and the response path is established, the regular characteristics of the intervention effect are reflected through the combination of multiple indexes, and then the induction analysis result set covering the whole treatment process is generated, thereby providing clear data basis for dynamic intervention evaluation and treatment path adjustment.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

The invention belongs to the field of biotechnology products for plant virus detection, and particularly relates to a double-antibody sandwich enzyme-linked immunosorbent assay kit for grape berry necrosis viruses, a preparation method and a detection method.The double-antibody sandwich enzyme-linked immunosorbent assay kit comprises a microwell plate for ELISA, an enzyme-labeled antibody, a buffer solution, a developing solution and a stop buffer, the microwell plate is coated with a GINV specific polyclonal antibody, and the microwell plate is coated with a GINV specific polyclonal antibody. The enzyme-labeled antibody is a GINV specific polyclonal antibody labeled by horse radish peroxidase. The immunogen adopted by the invention is a GINV coat protein antigen expressed by genetic engineering. The invention provides a rapid, sensitive, simple and convenient method for detecting the grape berry necrosis virus on the serological level, is economical and practical, and also provides an effective method for preventing and treating the grape berry necrosis virus in grape production and preparing virus-free seedlings of the grape berry necrosis virus.

The invention discloses an osteonecrosis early diagnosis kit based on blood detection and a biomarker, and the osteonecrosis early diagnosis kit can be used for early diagnosis of osteonecrosis through multi-omics screening based on femoral head necrosis lesion division, serological analysis of different stages of cases and cell and animal level biological tests in combination with actual detection result verification. It is determined that a group of biomolecules, namely PEBP1, ACAT1, MMP2, SOD1 and FN1 proteins, can be used for early diagnosis of osteonecrosis.

The present invention provides a method and system for evaluating the response after liver tumor intervention based on a generative adversarial network. A method for evaluating the response after liver tumor intervention based on a generative adversarial network includes the following steps: S1. Training a deep learning model to obtain an evaluation model capable of giving a prognosis evaluation result; S2. The evaluation model takes the plain CT scan after liver surgery and the postoperative serological test information as inputs and outputs a prognosis evaluation result. The present invention does not require liver puncture, which can reduce the trauma risk and medical resources for patient prognosis estimation; after the operation, the patient of the present invention does not need to take enhanced CT, and there will be no radiation risk and medical resource consumption caused by taking enhanced CT. At the same time, it can give a prognosis evaluation result based on enhanced CT, ensuring that the CT image used as the evaluation basis can clearly show the lesion, having the effect of enhanced CT, and being able to give a more accurate evaluation result.

The invention belongs to the technical field of biology, and particularly relates to a bispecific antibody targeting African swine fever virus and hog cholera virus and application of the bispecific antibody, the bispecific antibody shows high binding capacity to p30 protein of the African swine fever virus and E2 protein of the hog cholera virus, and it is indicated that the bispecific antibody can recognize the African swine fever virus and the hog cholera virus at the same time. When the bispecific antibody disclosed by the invention is used for preparing a detection product, double-flux detection of screening African swine fever viruses and swine fever viruses can be realized at the same time through one-time detection, and a new thought is provided for multiple detection of swine disease serology.

The invention relates to a serum marker for predicting glycolipid metabolism and a fat function. The serum marker is FBLN7. As a novel serological marker, the FBLN7 can specifically reflect changes of glycolipid metabolism and fat functions, changes of the serum level of the FBLN7 are closely related to occurrence and development of glycolipid metabolism disorder, and an important basis is provided for early diagnosis of diseases.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

The application relates to an AI-assisted result interpretation micro-sample detection kit for cutaneous leishmaniasis infection and an antibody detection method, and belongs to the technical field of serological immunodetection. The kit comprises an antibody detection platform for micro-samples, micro-bead probes, a washing solution, an antibody diluent, F594-labeled sheep anti-rat antibodies, positive quality control serum and negative quality control serum; the spherical probes are adopted in the application, the antigen-antibody combination efficiency is improved in space, and the antigen-antibody collision probability is effectively improved. Meanwhile, the micro-beads form a micro-scale mass transfer network in the reaction cavity, fluid mixing is enhanced, the reaction time is shortened, and the overall residence time and consumption of samples and reagents in the microfluidic channel are reduced. The application also introduces an AI-assisted result interpretation system to assist in result interpretation, significantly improves the friendliness and accessibility of the detection process, the classification model based on artificial intelligence has stronger robustness and judgment consistency, and has good market development value and popularization and application prospect.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

This invention discloses a risk prediction device and storage medium for metabolic-associated fatty liver disease in children or adolescents. The two-stage cascaded screening strategy and model of this invention provide a highly accurate, accessible, and scalable solution for the early identification of metabolic-associated fatty liver disease in children or adolescents. This invention utilizes different anthropometric data to identify high-risk groups in routine school physical examinations, followed by further screening using a comprehensive serological index at community health centers, thereby achieving accurate diagnosis of metabolic-associated fatty liver disease and providing clinicians with a non-invasive auxiliary diagnostic tool that combines high precision, high accuracy, and broad accessibility.